Warren-based pharmaceutical company Aquestive Therapeutics Inc. announced the appointment of Thomas A. Zalewski as chief legal officer and chief compliance officer, effective April 2.
He succeeds Lori J. Braender, who will be stepping down from both roles and will remain as corporate secretary of the company.
Zalewski brings extensive experience advising life sciences and health care companies on strategic, commercial and regulatory matters.
He is a partner at Day Pitney LLP, where he serves as chair of the firm’s Healthcare and Life Sciences practice. Zalewski has considerable experience advising life sciences, technology and health care companies on a broad range of strategic and commercial matters.
“(Zalewski’s) deep expertise in life sciences law, his track record advising companies at critical stages of their development and his familiarity with our company make him ideally suited to support our mission as we advance Anaphylm, the first and only oral epinephrine rescue medication, toward approval for patients around the world,” said Daniel Barber, president and chief executive officer of Aquestive.
Zalewski has also served as outside general counsel to emerging and middle-market companies, and previously served as a senior member of the legal team at Dendrite International, Inc. (now IQVIA).
He received a B.A. from Rutgers University and a J.D. from Seton Hall University School of Law.
Braender joined Aquestive Therapeutics in September 2018 as chief legal officer, chief compliance officer and secretary. Before joining the company, she was an attorney at Day Pitney LLP for 35 years.
She received a Bachelor of Science from Rider University and a J.D. from Seton Hall University School of Law.
